

Stanhope Capital Fortnightly Bulletin

Period ending 15 March 2021

Tactical Positioning

Over the last two weeks we have been adding exposure to US banks across our portfolios mainly funded by realising some profits in our quality growth funds. The major US banks offer a good hedge against gradually rising interest rates at a time when their balance sheets are in robust shape, bolstered by the ample stimuli during the pandemic. Excess bank capital, calculated to be at around 18%, should lead to large share re-purchase programmes and dividend increases which combined with relatively cheap valuations creates an attractive opportunity.

Market Moves

	Equities (incl. Dividends)						
15-Mar-21	World (\$)	US (\$)	Europe ¹ (€)	UK (£)	Japan (¥)	EM (\$)	Asia (\$)
Month to Date	3.6%	4.2%	4.6%	4.5%	4.9%	0.5%	0.0%
Year to Date	5.9%	5.9%	6.1%	5.3%	8.8%	5.3%	5.4%
	Commodities			Currencies (vs. USD)			Gov't
	COM ² (\$)	Gold (\$)	WTI Oil (\$)	EUR	GBP	JPY	UST 10Y ³
Month to Date	0.8%	-0.1%	6.3%	-1.2%	-0.2%	-2.4%	20bps
Year to Date	10.1%	-8.8%	34.8%	-2.3%	1.7%	-5.3%	69bps

¹ Europe excluding UK

² Bloomberg Commodity Index

³ US Treasury 10 Year Yield shows absolute, not percentage, change in yield

Source: Bloomberg

The fortnight saw an extension of this year's major themes in financial markets with a continued rotation out of growth stocks that have dominated the past decade, into more cyclically-oriented value stocks. US government bond yields continued to rise with the benchmark 10-year yield finishing the fortnight at 1.6%, the highest level since January 2020. The move has been driven by expectations of higher growth and inflation, and also higher real yields, which have helped stop the fall in the US dollar, at least for now. We expect US bond yields to rise further given the economically supportive backdrop of COVID vaccinations, a newly passed \$1.9 trillion stimulus package and stimulative monetary policy,

Markets have been in a febrile mood with frequent trend reversals and correlations breaking down. The first week of March saw bonds and equities selling off in tandem as investors feared higher US bond yields reducing the relative attractiveness of equities and other rate-sensitive risk assets. US Federal Reserve ("Fed") officials publicly communicated their relaxed stance towards higher bond yields, seeing them as a sign of a recovering economy. This was damaging to market sectors that have benefitted from low bond yields such as US technology stocks. The second week of March saw government bonds regain some composure with yields coming back down slightly before a further sell-off ensued last Friday – crucially equities did not fall alongside bonds this time. These gyrations reflect the current uncertainties relating to the impact of the strong economic recovery expected this year. Will it lead to inflation that will cause the Fed to tighten monetary policy or is there enough slack in the economy that a strong recovery can occur without inflation and higher interest rates? We do not know the answer but are endeavouring to position portfolios to benefit from the economic recovery whilst maintaining exposure to longer term growth themes and assets that offer protection against the threat of inflation.

In terms of monetary policy, all eyes are now on the Fed meeting this week as we get an update on their policy stance and thinking regarding higher bond yields. Last week, the European Central Bank meeting proved to be a dovish surprise as they announced more aggressive bond buying to counter the rise in yields, which they see as

an unwelcome tightening of financial conditions. The Bank of Japan has also intervened in the market to keep yields down.

In the US, President Biden's \$1.9 trillion stimulus package has become law. This includes the supplemental \$300 weekly unemployment benefit (extended until September), \$1,400 stimulus payments to households, child tax credit, aid for local authorities, COVID response funding, housing assistance, school support and even a bailout for failing pension schemes. President Biden has promised that every adult in the US will be vaccinated by the end of May. The focus now turns to the administration's even larger infrastructure package, with proposals ranging from \$2-4 trillion.

While the UK continues to lead major developed countries in deploying vaccines, with the majority of those in their 50s now being vaccinated and 36% of the population having received at least a first shot, various countries in Continental Europe have temporarily suspended the use of the AstraZeneca vaccine owing to reports of blood clots occurring. This move appears overly cautious considering the number of blood clots in vaccinated people does not appear to be higher than would be expected normally, according to the European Medicines Agency. The twin impact is likely to be another delay in the rollout and a further weakening of public confidence in the vaccine, as this comes after a campaign of misinformation led by President Macron who had said the vaccine was "quasi-ineffective" in over-65s (this was subsequently retracted but the reputational damage remained).

Economic Updates

Broadly speaking, macroeconomic data reflected positive sentiment making its way into the real economy thanks to the vaccine rollouts and the economic rebound.

In the US, the Services and Manufacturing Purchasing Managers' Index ("PMI"), non-farm payrolls, unemployment, and job openings all outperformed market expectations. The New York Fed's Empire State Manufacturing survey hit 17.4 in March (vs. 15.0 expected), the strongest measurement since November 2018. In contrast US core inflation was a little lower than expected.

In Europe, the German and Eurozone manufacturing PMIs, German CPI, the Eurozone Services PMI, producer price inflation, Eurozone retail sales, Eurozone unemployment, German factory orders, investor confidence and Eurozone industrial production all came in above consensus forecasts, with only German retail sales and the German Services PMI disappointing. In the UK data was mixed. The Manufacturing and Construction PMIs and mortgage approvals were above market expectations whilst the Services PMI and industrial production were below.

Over in China, industrial production, retail sales, exports and imports were all well above market forecasts.

JONATHAN BELL
IVO COULSON
LEO SUCH
15 March 2021

Important Information

The information contained herein (the "Information") has been prepared by the Stanhope Group. The Stanhope Group comprises Stanhope Capital (Switzerland) SA and its subsidiaries, including Stanhope Capital LLP and Stanhope Capital SAS. Stanhope Capital (Switzerland) SA is a company incorporated in Switzerland and a member of the Swiss Association of Asset Managers (SAAM), a Self-Regulating Body approved by the Swiss Financial Market Supervisory Authority (FINMA). Stanhope Capital LLP is a limited liability partnership incorporated in England and Wales authorised and regulated by the Financial Conduct Authority (FCA). Stanhope Capital SAS is a "Société par Actions Simplifiées" incorporated in France and regulated by the Autorité de Marchés Financiers (AMF). Acceptance of delivery of any part of this Information constitutes acceptance to the conditions of this legal disclaimer.

The Information attached is being disclosed by the member of the Stanhope Group indicated in the Information and exclusively to the intended recipient (the "Recipient").

The Information does not constitute an offer to sell or a solicitation of an offer to buy any investment fund or other financial products. The Information does not constitute investment advice or advice with respect to the suitability of any investment.

Restrictions

The Information is private and confidential and provided for information purposes only. No part of the Information is to be distributed, copied or disseminated directly or indirectly to anyone other than the Recipient and its professional advisers (for the sole purposes of obtaining advice). The Information should not be relied upon for tax, auditing or other purposes. The Information is not intended for any person in any jurisdiction (by way of nationality, residence, domicile or otherwise) where the publication or availability of it would be in contravention of any applicable law or regulation.

Opinions, estimates and statements contained in the Information constitute judgments of the Stanhope Group at the time of their preparation and are subject to change without notice.

The value of investments can fall as well as rise; potential income or profits are accompanied by the possibility of loss. The Recipient may not receive back the original amount invested. Past performance is not a reliable indication of future results. Performance figures included in the Information are unaudited except where indicated. Please refer to the risk warning notes provided next to any performance figures included in the Information. In certain circumstances prices stated may be historic because of the delay in obtaining prices and/or valuations from third parties. Valuations are based on either market prices available at the time of the preparation of the Information or on the Stanhope Group's reasonable estimates thereof at the time made. Valuations based upon other models or assumptions or calculated as of another date or time may result in different values. The valuation or returns on investments in currencies other than the base currency of a client's account may increase or decrease as a result of currency fluctuations.

The Stanhope Group may recommend or make investments for its clients in illiquid or volatile instruments or funds which may carry a high degree of default risk or in funds which utilise leverage/gearing which can exaggerate performance and may lead to large falls in value.

Any description of any investment process or investment management process described in the Information may change from time to time at the discretion of the Stanhope Group or otherwise.

While reasonable skill, care and diligence have been taken to ensure that the Information was accurate as at the date of writing, the Stanhope Group has not verified and accepts no legal responsibility for any third-party Information. In addition, the Stanhope Group makes no representation, warranty, undertaking or guarantee, express or implied, as to the accuracy or completeness of the Information and opinions therein. No members of the Stanhope Group shall be responsible for or have any liability to any Recipient or third party for losses or damages (whether consequential, incidental or otherwise) arising (i) out of errors, omissions or changes in market factors, conditions or circumstances or (ii) from making any use of the Information.

The Information does not replace, supplement or amend the contractual documentation entered between the relevant member of the Stanhope Group and the Recipient, including but not limited to (i) the required qualifications of the Recipient in order for such Recipient to receive the Information and (ii) the disclaimers and limitation of liability contained in such contractual documentation. Further, the Information does not replace, supplement or amend the documentation applicable to any investment fund or other financial products referred to in the Information.

United Kingdom

To the extent that the Information is aimed at residents of the United Kingdom, the Information has been approved for issue in the United Kingdom by Stanhope Capital LLP. Stanhope Capital LLP's advice is categorised by the Financial Conduct Authority as "restricted" because it advises on investment funds, which are only one type of "retail investment product". Stanhope Capital LLP does not provide investment advice on other retail investment products, such as life insurance, stakeholder pensions or personal pension schemes.

France

Stanhope Capital SAS does not provide investment advice on retail investment products, such as life insurance, stakeholder pensions or personal pension schemes.

United States

The Information is not intended for residents of the United States or for any U.S. Person. The Information is not an offer to sell any securities to or for the benefit of United States persons or the solicitation of any offer to buy securities on the part of or for the benefit of any such United States persons. For the avoidance of doubt a U.S. Person does not include a U.S. Citizen resident outside the U.S.